PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 2001 March; 84(6): 796–801.
PMCID: PMC2363818

Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia

Abstract

We assessed a possible role for high-risk human papillomavirus (HPV) testing in the policy after treatment for cervical intraepithelial neoplasia (CIN) 2 or 3 (moderate to severe dysplasia). According to the Dutch guidelines follow-up after treatment consists of cervical cytology at 6, 12 and 24 months. Colposcopy is only performed in case of abnormal cervical cytology. In this observational study 184 women treated for CIN 2 or 3 were prospectively monitored by cervical cytology and high-risk HPV testing 3, 6, 9, 12 and 24 months after treatment. Post-treatment CIN 2/3 was present in 29 women (15.8%). A positive high-risk HPV test 6 months after treatment was more predictive for post-treatment CIN 2/3 than abnormal cervical cytology (sensitivity 90% and 62% respectively, with similar specificity). At 6 months the negative predictive value of a high-risk HPV negative, normal smear, was 99%. Largely overlapping, partly different groups of women with post-treatment CIN 2/3 were identified by HPV testing and cervical cytology. Based on these results we advocate to include high-risk HPV testing in monitoring women initially treated for CIN 2/3. In case of a high-risk HPV positive test or abnormal cervical cytology, colposcopy is indicated. All women should be tested at 6 and 24 months after treatment and only referred to the population-based cervical cancer screening programme when the tests are negative on both visits. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: human papillomavirus, cervical intraepithelial neoplasia, cervical dysplasia, post-treatment CIN, guidelines

Full Text

The Full Text of this article is available as a PDF (57K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Alvarez RD, Helm CW, Edwards RP, Naumann RW, Partridge EE, Shingleton HM, McGee JA, Hall JB, Higgins RV, Malone JM., Jr Prospective randomized trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia. Gynecol Oncol. 1994 Feb;52(2):175–179. [PubMed]
  • Benedet JL, Miller DM, Nickerson KG. Results of conservative management of cervical intraepithelial neoplasia. Obstet Gynecol. 1992 Jan;79(1):105–110. [PubMed]
  • Bigrigg A, Haffenden DK, Sheehan AL, Codling BW, Read MD. Efficacy and safety of large-loop excision of the transformation zone. Lancet. 1994 Jan 1;343(8888):32–34. [PubMed]
  • Bistoletti P, Zellbi A, Moreno-Lopez J, Hjerpe A. Genital papillomavirus infection after treatment for cervical intraepithelial neoplasia (CIN) III. Cancer. 1988 Nov 1;62(9):2056–2059. [PubMed]
  • Bollen LJ, Tjong-A-Hung SP, van der Velden J, Mol BW, ten Kate FW, ter Schegget J, Bleker OP. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol Oncol. 1999 Feb;72(2):199–201. [PubMed]
  • Chua KL, Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol. 1997 Jul;66(1):108–113. [PubMed]
  • Elfgren K, Bistoletti P, Dillner L, Walboomers JM, Meijer CJ, Dillner J. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol. 1996 Mar;174(3):937–942. [PubMed]
  • Gunasekera PC, Phipps JH, Lewis BV. Large loop excision of the transformation zone (LLETZ) compared to carbon dioxide laser in the treatment of CIN: a superior mode of treatment. Br J Obstet Gynaecol. 1990 Nov;97(11):995–998. [PubMed]
  • Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 Feb 12;338(7):423–428. [PubMed]
  • Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997 Mar;35(3):791–795. [PMC free article] [PubMed]
  • MacLean AB. Healing of cervical epithelium after laser treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol. 1984 Jul;91(7):697–706. [PubMed]
  • Mann CH, Kehoe S, Brown A, Luesley DM. A study of the follow up patterns of women treated for CIN 2 and 3 before and after the introduction of the 1992 guidelines. Br J Obstet Gynaecol. 1999 Nov;106(11):1126–1129. [PubMed]
  • Mitchell MF, Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris H, Silva E. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol. 1998 Nov;92(5):737–744. [PubMed]
  • Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999 Jul 3;354(9172):20–25. [PubMed]
  • Nuovo GJ, Pedemonte BM. Human papillomavirus types and recurrent cervical warts. JAMA. 1990 Mar 2;263(9):1223–1226. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK